Cargando…

Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients

Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and M...

Descripción completa

Detalles Bibliográficos
Autores principales: Million, Matthieu, Lagier, Jean-Christophe, Hourdain, Jérôme, Franceschi, Frédéric, Deharo, Jean-Claude, Parola, Philippe, Brouqui, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220868/
https://www.ncbi.nlm.nih.gov/pubmed/37241095
http://dx.doi.org/10.3390/medicina59050863
_version_ 1785049320410578944
author Million, Matthieu
Lagier, Jean-Christophe
Hourdain, Jérôme
Franceschi, Frédéric
Deharo, Jean-Claude
Parola, Philippe
Brouqui, Philippe
author_facet Million, Matthieu
Lagier, Jean-Christophe
Hourdain, Jérôme
Franceschi, Frédéric
Deharo, Jean-Claude
Parola, Philippe
Brouqui, Philippe
author_sort Million, Matthieu
collection PubMed
description Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 ± 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 ± 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied.
format Online
Article
Text
id pubmed-10220868
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102208682023-05-28 Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients Million, Matthieu Lagier, Jean-Christophe Hourdain, Jérôme Franceschi, Frédéric Deharo, Jean-Claude Parola, Philippe Brouqui, Philippe Medicina (Kaunas) Article Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 ± 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 ± 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied. MDPI 2023-04-29 /pmc/articles/PMC10220868/ /pubmed/37241095 http://dx.doi.org/10.3390/medicina59050863 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Million, Matthieu
Lagier, Jean-Christophe
Hourdain, Jérôme
Franceschi, Frédéric
Deharo, Jean-Claude
Parola, Philippe
Brouqui, Philippe
Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
title Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
title_full Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
title_fullStr Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
title_full_unstemmed Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
title_short Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
title_sort cardiovascular safety of hydroxychloroquine–azithromycin in 424 covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220868/
https://www.ncbi.nlm.nih.gov/pubmed/37241095
http://dx.doi.org/10.3390/medicina59050863
work_keys_str_mv AT millionmatthieu cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients
AT lagierjeanchristophe cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients
AT hourdainjerome cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients
AT franceschifrederic cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients
AT deharojeanclaude cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients
AT parolaphilippe cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients
AT brouquiphilippe cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients